This site requires JavaScript to be enabled to work properly. Please modify your settings or use a different browser to continue

      

Leaving GSK Pro

You are leaving GSK Pro to visit a separate website not associated with GSK Pro, a portal for US Healthcare Professionals.There are website links to third-party sites on GSK Pro. GSK is not responsible for content on third-party websites.

Continue

Cancel

Storage & Dosing

SHINGRIX should be refrigerated. DO NOT FREEZE:

Store between 2°C and 8°C (36°F to 46°F) before reconstitution
(discard if frozen). After reconstitution, SHINGRIX is stable for 6
hours when kept between 2°C and 8°C (36°F to 46°F).1

SHINGRIX is supplied as an adjuvant and antigen for reconstitution:  

The antigen is to be reconstituted only with the accompanying adjuvant suspension. After reconstitution, administer SHINGRIX immediately or store refrigerated between 2°C and 8°C (36°F to 46°F) and use within 6 hours. Discard reconstituted vaccine if not used within 6 hours. Do not freeze. Discard if the reconstituted vaccine has been frozen.1

SHINGRIX is a recombinant vaccine for intramuscular injection only.1

SHINGRIX is administered as a 2-dose series:

The second dose should be administered anytime between 2 and 6 months after the first dose to complete the 2-dose series as directed.1

CDC has issued guidance on the SHINGRIX dosing schedule2,3,*

  • Following the first dose of SHINGRIX, the second dose should be given 2-6 months later  
  • If more than 6 months have elapsed since the first dose, administer the second dose as soon as possible. You should not restart the vaccine series  
  • However:
    • The efficacy of alternative dosing regimens has not been evaluated
    • Data regarding the safety of alternative regimens are limited
    • Individuals might remain at risk for herpes zoster during a longer than recommended interval between doses 1 and 2

Prescribing SHINGRIX

When referring patients to a pharmacy, e-prescribe SHINGRIX. The pharmacy will notify your office when the patient has received the first dose. See how you can make the most of your EHR system here.

  •   *In a phase 3 clinical study designed to help establish the dosing interval for SHINGRIX, all primary endpoints were met for dosing at a 0- and 6-month interval when compared to dosing at a 0-and 2-month interval. However, a co-primary endpoint (noninferiority) of the immune response was missed for dosing at a 0- and 12-month interval. (The upper limit of the 97.5% confidence interval was 1.53, above the predefined limit of <1.5.)4 GSK has not studied the safety or immune response of 3 doses of SHINGRIX in the indicated population (patients ≥50 years of age).1

CDC=Centers for Disease Control and Prevention.

 

You may also be interested in:

See how you and your staff can reconstitute SHINGRIX in four steps. Vaccinate confidently.

Watch a range of informative videos, including highlights of pivotal trials, MOA and reconstitution videos.

Get product coding and coverage details for commercial medical benefit and Medicare Part D insurance.

References: 1. Prescribing Information for SHINGRIX. 2. Centers for Disease Control and Prevention. Frequently asked questions About SHINGRIX. https://www.cdc.gov/vaccines/vpd/shingles/hcp/shingrix/faqs.html. Updated March 26, 2018. Accessed January 27, 2020. 3. Centers for Disease Control and Prevention. Recommendations of the Advisory Committee on Immunization Practices for use of herpes zoster vaccines. MMWR. 2018;67(3):103-108. 4. Lal H, Poder A, Campora L, et al. Immunogenicity, reactogenicity and safety of 2 doses of an adjuvanted herpes zoster subunit vaccine administered 2, 6 or 12 months apart in older adults: results of a phase III, randomized, open-label, multicenter study. Vaccine. 2018;36(1):148-154.

Trademarks are property of their respective owners.